Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

Phase 2

Completed

Conditions: Ovary Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00193297

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkins Lymphoma

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 40

Registration Number: NCT00193505

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Phase 3

Completed

Conditions: Genital Neoplasms, Female
Fallopian Tube Neoplasms
Ovarian Neoplasms
Pelvic Neoplasms
Peritoneal Neoplasms

Interventions: Drug: Gemcitabine
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2005-09-19

Last Posted Date: 2011-03-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 919

Registration Number: NCT00191646

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Malignant Tumor of Peritoneum

First Posted Date: 2005-09-19

Last Posted Date: 2011-02-25

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 165

Registration Number: NCT00189566

Locations: 🇫🇷
Hôpital Hotel Dieu, Paris, France

Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 18

Registration Number: NCT00193583

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Docetaxel
Drug: Gemcitabine
Drug: Carboplatin
Radiation: Radiation

First Posted Date: 2005-09-19

Last Posted Date: 2022-03-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 75

Registration Number: NCT00193427

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

Phase 3

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2005-09-19

Last Posted Date: 2014-01-10

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 976

Registration Number: NCT00189553

Locations: 🇫🇷
Hôpital Hôtel Dieu, Paris, France

Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2015-03-18

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 250

Registration Number: NCT00193310

Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel
Drug: carboplatin
Drug: cisplatin

First Posted Date: 2005-09-19

Last Posted Date: 2010-03-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 147

Registration Number: NCT00191854

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey

A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Herceptin

First Posted Date: 2005-09-19

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 150

Registration Number: NCT00191451

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy